##common.pageHeaderLogo.altText##

Review article

Vol. 155 No. 12 (2025)

Genotype-phenotype correlations in NTHL1-associated tumour syndrome: case report and literature review

Cite this as:
Swiss Med Wkly. 2025;155:4554
Published
04.12.2025

Summary

NTHL1-associated tumour syndrome, formerly known as NTHL1-associated polyposis, is a rare autosomal recessive tumour predisposition in which biallelic carriers of pathogenic NTHL1 variants develop multiple, predominantly adenomatous, polyps and have an increased risk of colorectal cancer and extracolonic tumour manifestations. The Nth like DNA glycosylase 1 (NTHL1) gene encodes for an enzyme involved in the base excision repair pathway which plays an important role in the maintenance of genomic integrity in the cell.

Upon identification of our first Swiss biallelic NTHL1 carrier, we performed a literature survey on mono- and biallelic NTHL1 carriers, followed by genotype-phenotype correlations in order to delineate the clinical manifestations and review current screening recommendations. A comprehensive literature search was conducted to identify all individuals with NTHL1 variants reported since the initial discovery in 2015 to 2022, followed by a genotype-phenotype analysis on a total of 216 individuals, 59 being biallelic and 157 monoallelic NTHL1 carriers. 81.4% of biallelic NTHL1 carriers presented with colon polyps, the majority (69%) exhibiting between 5 and 99 polyps. Interestingly, though not statistically significant, 19% (6/31; p = 0.0766) of carriers homozygous for the recurrent p.Gln90Ter variant displayed a classical (>100 polyps) polyposis phenotype compared to none of the compound heterozygous patients (n = 20); additionally, compound heterozygotes were diagnosed with breast cancer twice as often as homozygous women (75% vs 38.9%, p = 0.0717). Among biallelic carriers, colorectal carcinomas were reported in 50.8% (n = 30; median age at diagnosis: 49 years) and extracolonic malignancies in 55.9% (n = 33), with breast (53.3%), skin (27.1%), endometrial (16.7%) and bladder cancer (8.5%) being the most frequent. Among monoallelic NTHL1 carriers, 15.3% (n = 24) presented with colon polyps and 17.8% (n = 28; median age at diagnosis: 55 years) with colon carcinomas.

Timely surveillance measures are essential for early colorectal and breast cancer detection, treatment and prognosis. Prospectively gathered data are needed to further establish and refine clinical guidelines for individuals with NTHL1-associated tumour syndrome.

References

  1. 1. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, Spruijt L, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet. 2015 Jun;47(6):668–71. 10.1038/ng.3287
  2. 2. Boulouard F, Kasper E, Buisine MP, Lienard G, Vasseur S, Manase S, et al. Further delineation of the NTHL1 associated syndrome: A report from the French Oncogenetic Consortium. Clin Genet. 2021 May;99(5):662–72. 10.1111/cge.13925
  3. 3. Weren RD, Ligtenberg MJ, Geurts van Kessel A, De Voer RM, Hoogerbrugge N, Kuiper RP. NTHL1 and MUTYH polyposis syndromes: two sides of the same coin? J Pathol. 2018 Feb;244(2):135–42. 10.1002/path.5002
  4. 4. Krokan HE, Bjørås M. Base excision repair. Cold Spring Harb Perspect Biol. 2013 Apr;5(4):a012583. 10.1101/cshperspect.a012583
  5. 5. Imai K, Sarker AH, Akiyama K, Ikeda S, Yao M, Tsutsui K, et al. Genomic structure and sequence of a human homologue (NTHL1/NTH1) of Escherichia coli endonuclease III with those of the adjacent parts of TSC2 and SLC9A3R2 genes. Gene. 1998 Nov;222(2):287–95. doi: https://doi.org/10.1016/S0378-1119(98)00485-5
  6. 6. Das L, Quintana VG, Sweasy JB. NTHL1 in genomic integrity, aging and cancer. DNA Repair (Amst). 2020 Sep;93:102920. 10.1016/j.dnarep.2020.102920
  7. 7. Wallace SS, Murphy DL, Sweasy JB. Base excision repair and cancer. Cancer Lett. 2012 Dec;327(1-2):73–89. 10.1016/j.canlet.2011.12.038
  8. 8. Grolleman JE, de Voer RM, Elsayed FA, Nielsen M, Weren RD, Palles C, et al. Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-tumor Phenotype. Cancer Cell. 2019 Feb;35(2):256–266.e5. 10.1016/j.ccell.2018.12.011
  9. 9. Kuiper RP, Nielsen M, De Voer R, Hoogerbrugge N. NTHL1 Tumor Syndrome. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]Seattle (WA): University of Washington, Seattle; 2020. pp. 1993–2024. Available from https://www.ncbi.nlm.nih.gov/books/NBK555473/
  10. 10. Blatter R, Tschupp B, Aretz S, Bernstein I, Colas C, Evans DG, et al. Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers. Genet Med. 2020 Sep;22(9):1524–32. 10.1038/s41436-020-0826-1
  11. 11. Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, et al. The Human Gene Mutation Database (HGMD®): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020 Oct;139(10):1197–207. 10.1007/s00439-020-02199-3
  12. 12. Beck SH, Jelsig AM, Yassin HM, Lindberg LJ, Wadt KA, Karstensen JG. Intestinal and extraintestinal neoplasms in patients with NTHL1 tumor syndrome: a systematic review. Fam Cancer. 2022 Oct;21(4):453–62. 10.1007/s10689-022-00291-3
  13. 13. Nielsen M, Infante E, Brand R. MUTYH Polyposis. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]Seattle (WA): University of Washington, Seattle; 2021. pp. 1993–2024. Available from https://www.ncbi.nlm.nih.gov/books/NBK107219/
  14. 14. American Cancer Society A. Colorectal Cancer Facts & Figures 2020-2022. Atlanta: American Cancer Society; 2020. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf
  15. 15. Bundesamt für Statistik / Nationale Krebsregistrierungsstelle. Krebs, Neuerkrankungen und Sterbefälle: Anzahl, Raten, Medianalter und Risiko pro Krebsart 2016-2020 [Internet]. 12.12.2023. Available from: https://www.bfs.admin.ch/bfs/rm/home.assetdetail.29145337.html
  16. 16. Li N, Zethoven M, McInerny S, Devereux L, Huang YK, Thio N, et al. Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. NPJ Breast Cancer. 2021 May;7(1):52. 10.1038/s41523-021-00255-3
  17. 17. Macklin-Mantia SK, Clift KE, Maimone S, Hodge DO, Riegert-Johnson D, Hines SL. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results. J Genet Couns. 2023 Jun;32(3):598–606. 10. 1002/jgc4.1665 doi: https://doi.org/10.1002/jgc4.1665
  18. 18. Onkologie L. (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Endometriumkarzinom, Langversion 3.0, 2024, AWMF- Registernummer: 032-034OL. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/
  19. 19. Vogt S, Jones N, Christian D, Engel C, Nielsen M, Kaufmann A, et al. Expanded Extracolonic Tumor Spectrum in MUTYH-Associated Polyposis. Gastroenterology. 2009 Dec;137(6):1976-1985.e1-10. DOI: 10.1053/j.gastro.2009.08.052.
  20. 20. Belhadj S, Mur P, Navarro M, González S, Moreno V, Capellá G, et al. Delineating the Phenotypic Spectrum of the NTHL1-Associated Polyposis. Clin Gastroenterol Hepatol. 2017 Mar;15(3):461–2. 10.1016/j.cgh.2016.09.153
  21. 21. Elsayed FA, Grolleman JE, Ragunathan A, Buchanan DD, van Wezel T, de Voer RM, et al.; NTHL1 study group. Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer. Gastroenterology. 2020 Dec;159(6):2241–2243.e6. 10.1053/j.gastro.2020.08.042
  22. 22. Kumpula T, Tervasmäki A, Mantere T, Koivuluoma S, Huilaja L, Tasanen K, et al. Evaluating the role of NTHL1 p.Q90* allele in inherited breast cancer predisposition. Mol Genet Genomic Med. 2020 Nov;8(11):e1493. 10.1002/mgg3.1493